Articles with GBCA authors in the peer-reviewed scientific literature
Jeannine M. Salamone, Wanda Lucas, Shelley B. Brundage, Jamie N. Holloway, Sherri M. Stahl, Nora E. Carbine, Margery London, Naomi Greenwood, Rosa Goyes, Deborah Charles Chisholm, Erin Price, Roberta Carlin, Susan Winarsky, Kirsten B. Baker, Julia Maues and Ayesha N. Shajahan-Haq
Advocates bring unique and important viewpoints to the cancer research process, ensuring that scientific and medical advances are patient-centered and relevant. In this article, we discuss the benefits of engaging advocates in cancer research and underscore ways in which both the scientific and patient communities can facilitate this mutually beneficial collaboration.
Read more: Promoting Scientist–Advocate Collaborations in Cancer Research: Why and How (2018)
Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline (2018)
Gary H. Lyman, Heather Greenlee, Kari Bohlke, Ting Bao, Angela M. DeMichele, Gary E. Deng, Judith M. Fouladbakhsh, Brigitte Gil, Dawn L. Hershman, Sami Mansfield, Dawn M. Mussallem, Karen M. Mustian, Erin Price, Susan Rafte, and Lorenzo Cohen
The Society for Integrative Oncology (SIO) produced an evidence-based guideline on use of integrative therapies during and after breast cancer treatment that was determined to be relevant to the American Society of Clinical Oncology (ASCO) membership. ASCO considered the guideline for endorsement
Read more: Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO...
Nora E Carbine, Liz Lostumbo, Judi Wallace, Henry Ko
Recent progress in understanding the genetic basis of breast cancer and widely publicized reports of celebrities undergoing risk‐reducing mastectomy (RRM) have increased interest in RRM as a method of preventing breast cancer. This is an update of a Cochrane Review first published in 2004 and previously updated in 2006 and 2010.
Read more: Risk-reducing mastectomy for the prevention of primary breast cancer (2018)
ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization (2016)
Wrobel K, Zhao YC, Kulkoyluoglu E, Chen KL, Hieronymi K, Holloway J, Li S, Ray T, Ray PS, Landesman Y, Lipka AE, Smith RL, Madak-Erdogan Z. Mol Endocrinol. 2016 Oct;30(10):1029-1045. Epub 2016 Aug 17.
Most breast cancer deaths occur in women with recurrent, estrogen receptor (ER)-α(+), metastatic tumors. There is a critical need for therapeutic approaches that include novel, targetable mechanism-based strategies by which ERα (+) tumors can be resensitized to endocrine therapies.
Read more: ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular...
Page 1 of 2